Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07613931 | Evaluate Advanced Pneumatic Compression Device With Revised Compression Programming for Lymphedema Treatment | EARLY_PHASE1 | NOT YET_RECRUITING | 5 | — | — | Apr 1, 2026 | Sep 1, 2026 | May 29, 2026 | - | — |
• The distance (cm) that lymph travels from injection sites
• Number of lymph propulsion events per minute
| Arm | Type | Description |
|---|---|---|
| Treatment group | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Advanced pneumatic compression device (APCD) | DEVICE | Single APCD treatment session at visit 1 |
| Advanced pneumatic compression device (APCD) with revised compression programming | DEVICE | APCD with revised compression programming will be single treatment session at visit 2 |
| Indocyanine Green (IC-Green) | DRUG | Indocyanine Green dye will be used to assess primary endpoint |
Inclusion Criteria: 1. 18 years of age or older 2. A diagnosis of active lower extremity lymphedema, as assessed by medical history 3. Participant is a candidate for APCD treatment per the Flexitouch Plus indications for use 4. Must be able to provide informed consent prior to study participation 5...